Remove 2020 Remove Compounding Remove Immunization
article thumbnail

Roche rings Bicycle bell again, grabbing another cancer target

pharmaphorum

Genentech has been looking at the platform since 2020 under the terms of a deal worth up to $1.7 Genentech has been looking at the platform since 2020 under the terms of a deal worth up to $1.7 The time the peptides stay in the body can also be fine-tuned, allowing for precise control of drug exposure, according to the biotech.

Immunity 105
article thumbnail

XtalPi and CK Life Sciences to develop AI-driven tumour vaccine R&D platform

Pharmaceutical Technology

The platform could potentially forecast and design several tumour vaccines that can trigger certain immune responses to fight tumours. Additionally, the platform could produce preclinical tumour vaccine candidate compounds with strong immune activity by incorporating algorithmic feedback to streamline activity and efficacy.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

GSK partners LifeMine on fungi-derived medicines

pharmaphorum

GlaxoSmithKline has thrown its financial and drug development weight behind LifeMine Therapeutics, a US startup that aims to find new therapeutics from fungi – widely regarded as an underexplored resource of biologically-active compounds. Image by jggrz from Pixabay .

article thumbnail

Roche deepens ties with Jnana with a second licensing deal

pharmaphorum

Swiss pharma group Roche has doubled down on a partnership with Jnana Therapeutics, paying $50 million upfront to tap into the Boston-based biotech drug discovery platform for a wide-ranging push across cancer, immune-mediated, and neurological diseases.

article thumbnail

IO Biotech raises $155m to develop breakthrough cancer vaccine

pharmaphorum

The Series B fundraiser follows the FDA’s decision to grant Breakthrough Therapy designation last month for a combination of its lead immune-oncology therapies IO102 and IO103, with anti-PD-1 monoclonal antibodies for patients with metastatic melanoma.

article thumbnail

Cancer vaccines: providing the edge in oncology

pharmaphorum

Closely related to this is the fact that global spending on oncology drugs reached $164 billion in 2020, with drug sales growing at a compound annual growth rate of 14.3% While therapeutic cancer vaccines are able to help the body identify particular proteins expressed by cancer cells and then to instigate an immune response.

Vaccines 134
article thumbnail

Breaking New Ground in Migraine Prevention: Eptinezumab-jjmr

Pharmacy Times

On February 21, 2020, the FDA approved eptinezumab-jjmr (Vyepti; Lundbeck) as the first intravenous migraine preventative treatment for adults. Pharmacists are essential in managing access, patient education, and monitoring outcomes, ensuring adherence and addressing administrative challenges.

29